Vaxxinity (VAXX) Competitors $0.0001 -0.02 (-99.50%) As of 10/13/2025 02:25 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock VAXX vs. SCPS, NKGN, VRPX, TRVN, ARDS, STAB, NAVB, EVLO, GNCAQ, and GNCAShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Scopus BioPharma (SCPS), NKGen Biotech (NKGN), Virpax Pharmaceuticals (VRPX), Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Its Competitors Scopus BioPharma NKGen Biotech Virpax Pharmaceuticals Trevena Aridis Pharmaceuticals Statera Biopharma Navidea Biopharmaceuticals Evelo Biosciences Genocea Biosciences Genocea Biosciences Vaxxinity (NASDAQ:VAXX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment. Do insiders and institutionals believe in VAXX or SCPS? 82.9% of Vaxxinity shares are held by institutional investors. 64.1% of Vaxxinity shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, VAXX or SCPS? Vaxxinity has a beta of 17.1, meaning that its stock price is 1,610% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Does the media refer more to VAXX or SCPS? In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Vaxxinity Neutral Scopus BioPharma Neutral Is VAXX or SCPS more profitable? Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Scopus BioPharma N/A N/A N/A Which has preferable earnings & valuation, VAXX or SCPS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinityN/AN/A-$56.93M-$0.450.00Scopus BioPharmaN/AN/A-$11.61MN/AN/A SummaryVaxxinity beats Scopus BioPharma on 3 of the 4 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13K$787.62M$6.05B$10.30BDividend YieldN/A4.84%5.73%4.82%P/E Ratio0.001.2884.9827.10Price / SalesN/A29.85597.99133.24Price / CashN/A17.6425.7730.18Price / Book0.007.5412.516.69Net Income-$56.93M-$7.59M$3.32B$276.55M7 Day PerformanceN/A9.26%-0.07%-0.40%1 Month PerformanceN/A18.72%8.70%6.53%1 Year PerformanceN/A-12.60%76.28%41.04% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.00-99.5%N/A-97.5%$13KN/A0.0090Gap DownHigh Trading VolumeSCPSScopus BioPharmaN/A$0.00+233.3%N/AN/A$42KN/A0.009Gap UpNKGNNKGen Biotech0.1354 of 5 stars$0.00+20.0%N/A-96.4%$27KN/A0.00N/AGap UpVRPXVirpax Pharmaceuticals0.0517 of 5 stars$0.01flatN/A-99.8%$14KN/A0.007Gap UpTRVNTrevena1.6184 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$11KN/A0.0030STABStatera BiopharmaN/A$0.00+100.0%N/A-50.0%$11KN/A0.0020Gap UpNAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13K0.0010EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070 Related Companies and Tools Related Companies Scopus BioPharma Competitors NKGen Biotech Competitors Virpax Pharmaceuticals Competitors Trevena Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VAXX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
